Curiosity, Chemistry, and Crayfish: Sitting Down With Amorphical CEO Eden Ben
October 8, 2025
How military training and a fascination for nature have combined to build a sustainable business.
6 min read
False
Advertisement
Sitting Down With
The Golden Age of Drug Discovery
By Stephanie Vine
October 6, 2025
Sitting down with Insmed’s Tom Heightman, we discuss new technologies for drug discovery and the promise of human genome sequencing data.
7 min read
The Brutality of the Investment Landscape
By Stephanie Vine
September 11, 2025
Michael Murray has spent decades advising on deal management and commercial strategy – and he has a lot of tips and advice for budding start-ups looking for investment.
11 min read
Sustainability is Good Business: An Interview with Astellas
By Stephanie Vine
September 1, 2025
We speak with Adam Pearson, Chief Strategy Officer at Astellas, about the business of being green, success stories in Ireland, and helping local communities.
11 min read
From Pilot Dreams to Drug Development: Interviewing Subas Sakya
By Stephanie Vine
August 26, 2025
We sit down with the Chief Scientific Officer of BioDuro to find out what he wanted to be as a child and how he came to love drug development.
10 min read
AbbVie’s Eleni Lagkadinou on the Future of Cancer
By Stephanie Vine
July 14, 2025
What comes next for cancer drug development? AbbVie’s Eleni Lagkadinou discusses precision, AI, and her hope for turning cancer into a more chronic, manageable condition.
11 min read
Making Solid Progress: Sitting Down With 2025 Power Lister John Maher
July 4, 2025
Following another appearance in our 2025 Power List, we discuss the journey of John Maher, co-founder and CSO, Leucid Bio, from Michel Sadelain’s New York lab to King’s College London.
5 min read
Starting a Business in CRISPR
By Stephanie Vine
May 2, 2025
From a love of history books to a love of CRISPR, Monika Paule tells us the story of her career and the origins of Caszyme.
8 min read
Kite, CAR Ts, and Access for Patients
By Stephanie Vine
April 25, 2025
Depending on the country, only about two in 10 eligible patients, on average, receive CAR T-cell therapy. We sat down with Kite’s Cindy Perettie to talk about access to CAR Ts.
9 min read
Going From Benchtop Chemist to CEO: Part 2
By Stephanie Vine
April 21, 2025
In Part 1 of our interview with Simon Tasker, he explained how he joined Colorcon as a bench chemist – and never left...
5 min read
